Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter

Pharmacogenetics

Volumn 9, Issue 2, 1999, Pages 189-198

  Spire Vayron de la Moureyre, C Catherine ^a   Debuysère, Hervé ^a   Fazio, Fanny ^a   Sergent, Elodie ^a   Bernard, Claudine ^b   Sabbagh, Nada ^a   Marez, Delphine ^a   Lo Guidice, Jean Marc ^a   D'Halluin, Jean Claude ^b   Broly, Franck ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

5' Flanking region polymorphism; Single strand conformation polymorphism; Thiopurine S methyltransferase (TPMT); Variable number of tandem repeats

Indexed keywords

THIOPURINE METHYLTRANSFERASE;

ALLELE; ARTICLE; BINDING SITE; DNA FLANKING REGION; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; BASE SEQUENCE; COS CELLS; DNA PRIMERS; GENE FREQUENCY; HETEROZYGOTE; HUMANS; METHYLTRANSFERASES; MINISATELLITE REPEATS; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS);

EID: 0032805244     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bell GI, Selby M, Rutter WJ. The highly polymorphic region near the human insulin gene is composed of simple tandemly repeated sequences. Nature 1982; 295:31-35.
2. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goedderand DV. Complete nucleotide sequence of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 1983; 302:33-37.
3. Cotton RG. Current methods of mutation detection. Mutat Res 1993; 285:125-144.
4. Devlin B, Risch N, Roeder K. Estimation of allele frequencies for VNTR loci. Am J Hum Genet 1991: 48:662-676.
5. Evans WE, Horner M, Chi YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-delicient child with acute lymphocytic leukemia. J Pediatr 1991; 119:985-989.
6. Jeffreys AJ, Wilson V. Thein SL. Hypervariable minisatellite region in human DNA. Nature 1985; 314:67-73.
7. Krontiris TG, Devlin B, Karp DD, Robert NJ, Rish N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 1993; 329:517-523.
8. Krontiris TG. Minisatellites and human disease. Science 1995; 269:1682-1683.
9. Krynetski EY, Schuetz JD. Galpin AJ. Pui CH, Relling MV, Evans 1WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92:949-953.
10. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, Relling MV, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6:279-290.
11. Krynetski EY, Fessing MY, Yates CR, Sun D, Schuetz JD, Evans WE. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from the human PACI genomic library. Pharm Res 1997; 14:1672-1678.
12. Lee D, Szumlanski C, Houtman J, Honchel R, Rojas K, Overhauser J, et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos 1995; 23:398-405.
13. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM, Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987; 41:18-25.
14. Lennard L, Van Loon JA. Weinshilboum RM. Pharmacogenetics acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149-154.
15. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990: 336:225-229.
16. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69:577-579.
17. Maniatis T, Sambrook J, Fritsh EF. Commonly used techniques in molecular cloning. In: Ford N, Nolan C, Ferguson M, Oekler M, editors. Molecular cloning, a laboratory manual. New York: Cold Spring Harbor; 1989. pp. E1-E8.
18. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myclosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341:1151.
19. Orita M, Iwabana H, Kanazawa H, Hayashi K. Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86:2766-2770.
20. Otterness D, Szumlanski C, Weinshilboum RM. Human thiopurine methyltransferase pharmacogenetics: identification of a novel variant allele (abstract). J Invest Med 1996; 44:248.
21. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aabakke J. Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62:60-73.
22. Pascal E, Tjian R. Different activation domains of SpI govern formation of multimers and mediate transcriptional synergism. Genes Dev 1991; 5:1646-1656.
23. Ramel C. Mini- and microsatellites. Environ Health Perspect 1997; 105:781-789.
24. Schütz E, Gummert J. Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341:436.
25. Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N, Marez D, Vinner E, Alcaïde E, et al. An efficient PCR-SSCP strategy for detection of known and new mutations of the thiopurine S-methyltransferase gene. Hum Mutat 1998; 12:177-185.
26. Szumlanski C, Honchel R, Scott M, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992: 2:148-159.
27. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism, DNA Cell Biol 1996; 15:17-30.
28. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58:694-702.
29. Vuchetich JP, Weinshilboum RM, Price PA. Segregation analysis of human and red blood cell (RBC) thiopurine methyltransferase (TPMT) activity. Genet Epidemiol 1995: 12:1-11.
30. Weinshilboum R, Raymond F, Pazmino P. Human crythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85:323-333.
31. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651-662.
32. Woodson LC, Dunnette J, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunolitration studies. J Pharmacol Exp Ther 1982; 222:174-181.
33. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608-614.